LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1532 | 3694 | 0.4148 | 0.0251 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2912 | 3694 | 0.7884 | 0.6475 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3439 | 3694 | 0.9310 | 0.8850 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 4341 | 3694 | 1.1751 | 1.2918 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3032 | 3694 | 0.8209 | 0.7016 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3660 | 3694 | 0.9909 | 0.9848 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2134 | 3694 | 0.5778 | 0.2966 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3504 | 3694 | 0.9487 | 0.9146 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3556 | 3694 | 0.9626 | 0.9377 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2275 | 3694 | 0.6160 | 0.3602 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3644 | 3694 | 0.9865 | 0.9774 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1192 | 3694 | 0.3227 | -0.1284 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1143 | 3694 | 0.3096 | -0.1502 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1292 | 3694 | 0.3499 | -0.0830 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2661 | 3694 | 0.7205 | 0.5344 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2449 | 3694 | 0.6630 | 0.4385 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3666 | 3694 | 0.9926 | 0.9877 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP5 | 72 | hr | 1476 | 829 | 3694 | 0.2245 | -0.2920 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP6 | 72 | hr | 1476 | 834 | 3694 | 0.2258 | -0.2899 |
| SK-BR-3 | WYE-125132 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1411 | 3694 | 0.3820 | -0.0296 |
| SK-BR-3 | WZ3105 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1189 | 3694 | 0.3220 | -0.1296 |
| SK-BR-3 | XMD11-50 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2122 | 3694 | 0.5745 | 0.2912 |
| SK-BR-3 | Y39983 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2365 | 3694 | 0.6403 | 0.4008 |
| SK-BR-3 | YM 201636 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3060 | 3694 | 0.8285 | 0.7144 |
| SK-BR-3 | ZSTK474 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1478 | 3694 | 0.4002 | 0.0007 |